The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases by Karin Nielsen et al.
Nielsen et al. BMC Medical Imaging 2014, 14:27
http://www.biomedcentral.com/1471-2342/14/27STUDY PROTOCOL Open AccessThe use of PET-MRI in the follow-up after
radiofrequency- and microwave ablation of
colorectal liver metastases
Karin Nielsen1, Hester J Scheffer2, Indra C Pieters2, Aukje AJM van Tilborg2, Jan-Hein TM van Waesberghe2,
Daniela E Oprea-Lager2, Martijn R Meijerink2, Geert Kazemier1, Otto S Hoekstra2, Hermien WH Schreurs3,
Colin Sietses4, Sybren Meijer1, Emile FI Comans2 and Petrousjka MP van den Tol1*Abstract
Background: Thermal ablation of colorectal liver metastases (CRLM) may result in local progression, which
generally appear within a year of treatment. As the timely diagnosis of this progression allows potentially curative
local treatment, an optimal follow-up imaging strategy is essential. PET-MRI is a one potential imaging modality,
combining the advantages of PET and MRI. The aim of this study is evaluate fluorine-18 deoxyglucose positron
emission tomography (FDG) PET-MRI as a modality for detection of local tumor progression during the first year
following thermal ablation, as compared to the current standard, FDG PET-CT. The ability of FDG PET-MRI to detect
new intrahepatic lesions, and the extent to which FDG PET-MRI alters clinical management, inter-observer variability
and patient preference will also be included as secondary outcomes.
Methods/Design: Twenty patients undergoing treatment with radiofrequency or microwave ablation for (recurrent)
CRLM will be included in this prospective trial. During the first year of follow-up, patients will be scanned at the VU
University Medical Center at 3-monthly intervals using a 4-phase liver CT, FDG PET-CT and FDG PET-MRI. Patients
treated with chemotherapy <6 weeks prior to scanning or with a contra-indication for MRI will be excluded. MRI will
be performed using both whole body imaging (mDixon) and dedicated liver sequences, including diffusion-weighted
imaging, T1 in-phase and opposed-phase, T2 and dynamic contrast-enhanced imaging. The results of all modalities
will be scored by 4 individual reviewers and inter-observer agreement will be determined. The reference standard
will be histology or clinical follow-up. A questionnaire regarding patients’ experience with both modalities will also be
completed at the end of the follow-up year.
Discussion: Improved treatment options for local site recurrences following CRLM ablation mean that accurate
post-ablation staging is becoming increasingly important. The combination of the sensitivity of MRI as a detection
method for small intrahepatic lesions with the ability of FDG PET to visualize enhanced metabolism at the ablation
site suggests that FDG PET-MRI could potentially improve the accuracy of (early) detection of progressive disease,
and thus allow swifter and more effective decision-making regarding appropriate treatment.
Trial registration: Trial registration number: NCT01895673
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Thermal ablation techniques, including radiofrequency
ablation (RFA) and microwave ablation (MWA), are now
well-established therapeutic options for the localized treat-
ment of unresectable colorectal liver metastases (CRLM)
[1]. Although potentially curative in selected cases, these
techniques carry a risk of incomplete ablation and can
show local tumor progression (LTP) rates of up to 30%, of
which >95% are diagnosed within one year of ablation
[2-4]. Complete tumour clearance, and therefore potential
cure, can still be achieved in patients without extensive
intra or extrahepatic metastases through re-treatment of a
LTP [1,5].
Imaging plays a key role in diagnosing progressive dis-
ease following hepatic RFA and MWA, with post-ablative
lesions generally monitored using contrast-enhanced
computed tomography (ceCT) and magnetic resonance
imaging (MRI). Without proof of lesion growth from
consecutive scans, an important weakness of these mo-
dalities is the inability to distinguish between reactive
tissue surrounding the ablated lesion (post-ablation
effects) and viable tumour [6]. Diffusion-weighed (DW)
MRI outperforms ceCT in the initial detection of small
hepatic metastases (<1 cm) and is also superior to ceCT
in the detection of CRLM after treatment with systemic
chemotherapy without radiation load [7,8].
Due to the visualization of increased glucose metabol-
ism in tumour cells, fluorine-18 deoxyglucose positron
emission tomography (FDG-PET) is a useful tool in the
assessment of treatment response following RFA [6,9].
Ablated lesions that show focal FDG uptake in or within
1 cm of the ablated area are considered clinically suspect
for LTP [6,10]. However, as FDG-PET lacks an anatom-
ical reference it is less accurate in determining the exact
location of viable tumour tissue. A solution to this prob-
lem was found by combining FDG-PET and CT images
to provide fused functional and morphological data [11],
and PET-CT has since been shown to be superior to
ceCT in the identification of LTP [6,9]. Integrated PET-
MRI is a new imaging modality, combining the advan-
tages of FDG-PET with the ability of MRI to detect
small liver tumours without CT radiation exposure.
Recent results show that detection sensitivity for hepatic
metastases, through post hoc fusion of FDG-PET
images and 1.5 Tesla contrast-enhanced (Gadolinium)
MRI obtained from two different scanners, is signifi-
cantly higher than for PET-CT (93% and 76% respect-
ively, p = 0.02) [12]. PET-MRI appears to offer higher
lesion conspicuity and diagnostic confidence compared
to PET-CT [13], and this additional information can
influence clinical management of cancer patients The
combined advantages of detection of smaller hepatic
tumours with a higher sensitivity and detection of focal
FDG uptake suggestive for LTP indicates that PET-MRIcould provide complementary information and facilitate
improved clinical decision making [14].
To the best of our knowledge, the effectiveness of inte-
grated PET-MRI in RFA or MWA follow-up has not been
investigated. The primary aim of this study is therefore to
determine the accuracy of 18 F-FDG PET-MRI in LTP
detection. Secondary aims will be to investigate whether
PET-MRI is more accurate than PET-CT and ceCT in the
detection of new intra-hepatic lesions, and to evaluate
inter-observer variability, the impact of PET-MRI on fu-
ture treatment and patients’ views on both modalities. We
hypothesize that PET-MRI will be at least equivalent to
PET-CT in the diagnosis of LTP, but superior to PET-CT
in the early detection of new intrahepatic lesions and
therefore able to positively influence decision making in
patients with RFA/MWA-treated CRLM.Methods/Design
Design
This prospective study has been approved by the Med-
ical Ethical Review Board of the VU University Medical
Center. The study is investigator-sponsored, independent
of industry and is registered at clinicaltrials.gov under
number NCT01895673.Primary and secondary objectives
We will assess the effectiveness of FDG PET-MRI in the
follow-up of thermal ablation (RFA/MWA) of CRLM.
Our primary aim will be to assess the accuracy of FDG
PET-MRI in the diagnosis of local progression in the
first year after RFA/MWA of CRLM. Therefore, all FDG
PET-MRI images will be compared to FDG PET-CT and
4-phase liver CT images, which are the current standard
of care. Results of different imaging sets will be compared
on a per-patient and a per-lesion base. These results will
then be compared to a reference standard: either histo-
logical outcome (if available) or clinical follow-up.
Secondary outcomes will include the accuracy of diag-
nosis of new intrahepatic disease after RFA/MWA. Since
only a single 18 F-FDG per combined PET-MRI and PET-
CT visit will be applied, we will have the opportunity to
investigate whether dual-time point PET can increase the
specificity of the 18 F-FDG signal and increase diagnostic
accuracy [15]. The reproducibly and robustness of inter-
observer variation will also be determined. Clinical rele-
vance will be studied by recruiting a panel consisting of a
radiologist, interventional radiologist, nuclear medicine
physician, oncologist, oncological surgeon and a radiation
oncologist to retrospectively review PET-MRI images and
agree on the preferred treatment. Choice of treatment
based on PET-MRI will then be compared to the treat-
ment that was actually received based on PET-CT and
4-phase liver CT. Finally, patients’ preferences will be
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questionnaire that compares both modalities (Table 1).
Patients
Written informed consent will be obtained from all
participants. Patients scheduled to undergo either RFA/
MWA of CRLM, solely or in combination with resec-
tion, or RFA/MWA for LTP after previous thermal abla-
tion of CRLM, will be recruited at a referral university
hospital (VU University Medical Center, Amsterdam, the
Netherlands) and a large community teaching hospital
(Gelderse Vallei, Ede, the Netherlands). Assessment prior
to ablation consists of a full-body 18 F-FDG PET-CT
and 4-phase liver CT or MRI of the liver. Increased FDG
uptake of the CRLM on the pre-operative PET scan is a
requirement. All patients will be discussed by a multidis-
ciplinary liver board prior to treatment and suitability
for RFA or MWA will be at their discretion. TreatmentTable 1 Questionnaire comparing PET-CT and PET-MRI
(completed following fourth PET-MRI)
Questions about the PET-MRI
It was comfortable 0 1 2 3 4 5 n/a
I felt scared 0 1 2 3 4 5 n/a
It took too long 0 1 2 3 4 5 n/a
The noise bothered me 0 1 2 3 4 5 n/a
I was reluctant to undergo the scan 0 1 2 3 4 5 n/a
It went better than expected 0 1 2 3 4 5 n/a
The PET-MRI contrast agents caused
discomfort
0 1 2 3 4 5 n/a
Questions about the PET-CT
It was comfortable 0 1 2 3 4 5 n/a
I felt scared 0 1 2 3 4 5 n/a
It took too long 0 1 2 3 4 5 n/a
The noise bothered me 0 1 2 3 4 5 n/a
I was reluctant to undergo the scan 0 1 2 3 4 5 n/a
It went better than expected 0 1 2 3 4 5 n/a
The PET-CT contrast agents caused
discomfort
0 1 2 3 4 5 n/a
Comparing PET-CT to PET-MRI
The PET-MRI was less of a burden than
the PET-CT
0 1 2 3 4 5 n/a
It didn’t matter that the PET-MRI took
longer than the PET-CT
0 1 2 3 4 5 n/a
If the results are equally good, I prefer
the PET-MRI over the PET-CT
0 1 2 3 4 5 n/a
If the results of the PET-MRI are better
than the PET/CT, I would prefer the
PET-MRI over the PET-CT
0 1 2 3 4 5 n/a
Comments
0: Don’t know. 1: Strongly disagree. 2: Disagree. 3: Neither agree nor disagree.
4: Agree. 5: Strongly agree. n/a: not applicable.will depend, amongst others things, on the number, loca-
tion and size of lesions. An open approach using intra-
operative ultrasound is preferred as an initial treatment,
and a CT-guided percutaneous approach will be used for
treatment of recurrences. Technical success, or was the
tumor ablated according to protocol, was required before
inclusion [16]. Our protocol defines a complete ablation
as the entire size of the tumor plus a 1 cm tumor free
margin as seen on IOUS or CT. This area was calculated
during the planning phase of the procedure.
Exclusion criteria are chemotherapy within 6 weeks
prior to the first scan, allergies to contrast media and
general contraindications for MRI. Patients with an eGFR
<60 will be admitted for additional hydration before and
after the scans. If chemotherapy is initiated or if the ab-
lated lesion is resected during the first year of follow-up,
participation in the study will be aborted.Study procedure
The standard follow-up protocol during the first year after
RFA/MWA of CRLM in the VU University Medical Cen-
ter consists of three-monthly whole-body FDG PET-CT
and 4-phase liver CT, in combination with measurement
of serum carcinoembryonic antigen (only when elevated
pre-operatively). For the purposes of this study, liver FDG
PET-MRI will be added to the routine procedure, using a
3.0 Tesla Ingenuity TF Philips scanner (Philips Medical
Systems, Cleveland, OH). This hybrid PET-MRI system
is characterized by a sequential acquisition mode and
has separate scanners with a turntable patient handling
system facilitating patient motion between the MRI and
the PET gantries that are located at a 3 meter distance
from each other.
At the end of one year follow-up, patients will be asked
to complete a questionnaire evaluating their experience
with the PET-MRI compared to the PET-CT. The study
procedure is illustrated in Figure 1.Imaging
A summary of imaging steps is provided in Table 2. PET
imaging will be conducted according to EANM guidelines
[17]. 18 F-FDG will be administered while the patient is
supine on the PET-MRI table using MR compatible
devices. The MRI will be performed during the period in
which FDG distributes throughout the body, and PET will
commence approximately 60 minutes after FDG injection.
The PET of the PET-CT will follow 20 minutes (±5) after
completion of the PET-MRI, followed by a whole body
low-dose CT for attenuation and image-fusion and a
diagnostic 4-phase liver CT. This scanning sequence has
been chosen to minimize the burden for the patient, to
optimize reliability of the dedicated liver MRI sequences
and to minimize the time between both PET scans.
Figure 1 Flow diagram of study procedure.
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A 16-channel Sense Torso XL coil is connected and a
low-resolution non-diagnostic MR attenuation sequence
(atMRI) (skull base to mid-thigh) is run, followed by a
whole body T1-weighted mDixon sequence, scanned in
the axial plane to allow for anatomical matching of FDG
images [18]. These images are routinely reconstructed
in the coronal plane. Dedicated axial liver imaging is
performed: axial T2-weighted TSE (TR/TE 850/80 msec);
T1 in- and opposed phase GRE (TR/TE 180/2.3/1.15 msec)
and diffusion-weighted imaging (TR/TE 2407/53 msec)
using b-values (0, 50 and 800 sec/mm2). This is followed by
a fat-suppressed T1-weighted GRE using IV Gadolinium-
chelate at 0.1 mmol/kg (Dotarem, 0.5 mmol/ml; Guerbet,
Gorichem, The Netherlands) in 4 separate phases: pre-
contrast, arterial phase (determined by a bolus tracking
method to ensure optimal arterial enhancement, which in-
cludes full enhancement of the hepatic artery and only par-
tial enhancement of the portal vein [19]), as well as 70 and200 msec post-injection. Total imaging time for the
dedicated liver protocol is approximately 45 minutes.
18F-FDG PET (PET-MRI)
After MRI, the PET-MRI table is turned and the patient
is placed in the PET gantry. The PET features an 18 cm
axial field of view, 9 cm overlap between bed positions
and a 5.5 mm reconstructed isotropic spatial resolution.
The scan trajectory covers the skull base to mid-thigh,
taking 2 min/bed position. Reconstructed images have
an image matrix size of 144X144, voxel size of 4X4 mm
and slice thickness of 5 mm. Data are reconstructed by
means of a Blob-OS-TF algorithm. Fusion images are
created with the PET sequence and atMRI, mDixon
axial and coronal whole body and axial T2 liver.
18F-FDG PET (PET-CT)
The Philips Gemini TF PET-CT system (Philips Medical
Systems, Cleveland, Ohio, USA) is comparable to the
Table 2 Imaging protocol and timeline of PET-MRI and
PET-CT (T = approximate time in minutes)
T = 0 Injection FDG
T = 5 Start MRI Axial T2-weighted imaging





- arterial phase (bolus tracking)
- portovenous phase (70 sec delay)
- late venous phase (200 sec delay)
Attenuation sequence (skullbase – midthigh)
Whole body T1-weighted mDixon
(skullbase – midthigh)
T = 60 PET skullbase – midthigh
T = 75 End PET-MRI Transfer to PET-CT




- arterial phase (bolus tracking)
- portovenous phase (70 sec delay)
- late venous phase (240 sec delay)
T = 145 End PET-CT
Table 3 Test positivity criteria for progressive disease on
different imaging modalities; ≤1 cm of the ablation zone
(LTP) / >1 cm of the ablation zone (new intrahepatic
recurrence)
ceCT Newly detectable hypodense lesion
MRI T1 New focal hypo-intense lesion
T2 New focal hyper-intense lesion
Contrast enhanced Irregular peripheral enhancement pattern
of a circumscribed lesion
Diffusion weighed Lesion with high signal intensity on b800
FDG PET Lesion with clearly increased focal uptake
as compared to liver background
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whole body PET (skull base to mid-thigh), with data
being reconstructed by means of a raw action ordered
subset expectation maximization algorithm using default
reconstruction parameters. Time of flight (TF) informa-
tion is used during reconstruction. Reconstructed images
have an image matrix size of 144X144, a voxel size of
4X4 mm and a slice thickness of 5 mm. The acquisition
time per bed position is adjusted for the time interval
between the start of PET-CT and FDG injection and will
usually be 2–3 min/bed position.
Low-dose CT
This is followed by a low-dose CT for attenuation and
image fusion and is collected using a beam current of 30–
50 mAs at 100 keV. The low-dose CT is reconstructed
using an image matrix of 512X512, resulting in voxel sizes
of 1.17X1.17 mm and a slice thickness of 5 mm.
4-phase liver CT
A diagnostic 4-phase CT of the liver using 100 ml Xene-
tix300 (Guerbet, Villepinte, France) is subsequently per-
formed, using a beam current of 175-220mAs per slice.
First, a precontrast scan is run, followed by the arterial
phase using a bolus-tracking method and a 80 keV scanto ensure optimal arterial enhancement [20]. During the
venous phase, 70 sec post-injection, the entire abdomen
is scanned, followed by a scan of the liver in the late
venous phase (240 sec post-injection), both at 120 keV.
The images are reconstructed using a matrix of 512X512
and a slice thickness of 3–5 mm. All images are sent to a
digital picture archive and communication system (PACS;
Sectra AB, Linköping, Sweden).
Image analysis
Only PET-CT and 4-phase liver CT images will be
analysed and used in the context of routine patient care
during clinical follow-up. The PET-MRI images will not
be part of the diagnostic and follow-up process.
For imaging analysis, blinded data sets of all scans will
be viewed both separately and independently by two
designated, experienced radiologists and two nuclear
medicine physicians. The reviewers will be blinded to the
results of the other imaging modalities and to final patient
outcome. A time-interval of at least four weeks will be in-
troduced between the first and second review. Progressive
disease will be scored on a per-patient and per-lesion
basis, and results of all imaging modalities will be com-
pared. The criteria for progression on different modalities
are defined in Table 3. Each lesion on each modality will
be scored on a separate form and results will be scored
from 1–5 (Table 4) and size and location of the lesions will
be reported. A LTP is defined as a lesion located in or
within 1 cm of the ablation zone; a new intrahepatic lesion
is defined as a lesion located more than 1 cm distant from
the ablation zone [6]. On MRI, a suspicious lesions has to
meet the definition of LTP in at least two different
sequences before it is considered positive for progression.
Recurrent disease and repeated treatment
If recurrent disease is suspected on either 4-phase CT of
the liver or on PET-CT, the patient will be evaluated for
re-treatment by our multidisciplinary liver board. If
either resection of a LTP or chemotherapy is indicated,
the patient will be excluded from further participation in
Table 4 Study form for reviewers’ results (per lesion
base)
Study number: Reviewer number:
Score Definition Explanation
1 Normal Confident that no tumor recurrence is
present in the ablation zone/confident
that no new intrahepatic lesions are
present
2 Probably benign The appearance of the ablated lesion is
compatible with post-ablational inflam-
mation or rim-like characteristics/the
new lesions diagnosed do not appear
malignant
3 Equivocal There is doubt whether the enhanced
FDG, CT- and/or MRI features indicate
tumor progression or inflammation/
there is doubt whether the new lesions
diagnosed are benign or malignant
4 Probably malignant Confident of local progression in the
ablation zone/confident of new
intrahepatic metastases
Size or estimated size:
Location:
Intensity FDG vs normal liver; slight/
moderate/intense
5 Impaired quality Quality of the images precludes
adequate diagnosis
Comments:
Nielsen et al. BMC Medical Imaging 2014, 14:27 Page 6 of 9
http://www.biomedcentral.com/1471-2342/14/27the study. If patients are eligible for repeated RFA/MWA
treatment of the LTP, study participation will be contin-
ued. Patients with new intrahepatic lesions that are eligible
for local treatment (surgery or ablation) will remain in the
study, as long as the initially ablated area remains un-
affected (Figure 1). Prior to re-treatment with RFA/MWA,
several biopsies will be taken from the suspected area for
pathological confirmation. To minimize the chance of
‘track seeding’, tract ablation will be performed after the
procedure. Extra-hepatic disease will be treated as deemed
suitable. If there is any doubt as to whether an imaging
feature indicates recurrent disease, the scan will be
repeated after 3 months as a confirmation.
Sample size calculation
Sample size estimates are based on the incidence of local
site recurrences and new intrahepatic metastases. Previ-
ous studies have shown that 25-40% of the patients
treated with RFA/MWA develop LTP, of which >95%
occur within the first year [4]. In addition, 30-40% of the
patients will develop new intrahepatic metastases [2,21].
At least 5 LTP and 5 new intrahepatic lesions are neces-
sary for a meaningful comparison between PET-CT and
PET-MRI in this observational study. Using the binom-
inal distribution (with p = 0.35 and n = 20), the chance of
finding 5 LTP and the chance of finding 5 new intrahepa-
tic lesions in our population are both 88%. This suggeststhat the study has a satisfactory chance of success with a
sample size of 20 patients. Patients excluded during the
study period will be replaced by new participants, so that
20 patients will have completed one year follow-up at
study completion.
Statistical analysis
We will determine the accuracy of PET-MRI for
diagnosing recurrent disease compared to each imaging
method (MRI, CT and PET-CT) and compared to path-
ology or clinical follow-up. Continuous variables will be
summarized with standard descriptive statistics including
means, standard deviations, medians and ranges when in-
dicated. Categorical variables will be summarized with
frequencies. McNemar’s test is used to determine agree-
ment between PET-MRI and other modalities. The inter-
observer variability will be quantified with Cohen’s Kappa
and proportions of specific agreement. P-values less than
0.05 will be considered statistically significant. Statistical
analysis will be performed using SPSS version 20.0 (SPSS
Inc, Chicago).
Discussion
Accurate staging is the foundation of prognostic out-
comes in oncology and has an immediate effect on pa-
tient care in every phase of disease. Although the quality
of imaging has improved considerably over the past
decades, the search for optimized modalities for specific
indications continues. Although the recent introduction
of PET-MRI combines the major advantages of both tech-
niques, the value of PET-MRI in staging for the onco-
logical patient still has to be proven. Ours will be the first
study to assess the value of PET-MRI in the follow-up of
thermal ablation of CRLM.
Early diagnosis of small volume recurrences is the
primary goal of intense surveillance strategies following
local hepatic tumor ablation. Treatment of these LTP and
of new intra-hepatic lesions may allow complete tumor
eradication and therefore provide potential cure in pa-
tients treated for CRLM [5]. To detect recurrent disease at
an early stage, we advocate a local surveillance protocol
with intensive follow-up over the 12-month period in
which most recurrences occur [4]. Although numerous
studies have attempted to define an optimal imaging
algorithm after local treatment of liver metastases, the
frequency, duration and survival benefit of surveillance
have not yet been formally proven and general consensus
is lacking [22,23]. To the best of our knowledge, no
prospective studies comparing follow-up schemes after
RFA or MWA have yet been published.
PET-CT has proven value in the imaging-based diag-
nosis of recurrent disease following RFA/MWA of liver
malignancies, and repeat treatment is often initiated
solely based on this imaging modality.
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a recurrence detected by imaging has long been a sub-
ject of debate within the thermal ablation field. We will
therefore take multiple biopsies of the suspected area,
taking into account the possibility of sampling necrotic
tissue rather than active tumor tissue (sampling error).
A sampling error of this type may influence our calcula-
tion of the specificity of PET-MRI, because false-positive
results cannot be completely ruled out. The reference
standard (in addition to pathology) for imaging accuracy
will be the presence or absence of recurrent disease at
clinical follow-up in the first year.
The period between FDG injection and acquisition of
the PET-CT in this study is 30 minutes longer than the
standard protocol, which might increase our ability to de-
tect intrahepatic malignancies. Background activity in the
normal liver parenchyma due to high glucose metabolism
and abundant expression of Glut-1 and Hexokinase II can
often impede detection of liver lesions. Following a ration-
ale that FDG accumulates over time in malignant cells as
compared to healthy or inflamed hepatocytes, several au-
thors have proposed that PET-CT imaging may improve
lesion detectability over time through an improvement in
the tumor-to-background ratio [24,25]. It is known that
FDG uptake by a tumor may not plateau before 90–120
minutes and peak levels may persist for up to 4 hours after
injection [26]. Using target-liver ratios, we will investigate
whether the 30 minutes delay between both PET-scans
contribute to an improved differentiation of post-ablation
inflammation and residual tumor [15]. The study has not
been designed to provide semi-quantitative values for
FDG uptake as predictors of therapeutic response, gen-
erally expressed as the standard uptake volume (SUV).
However, the SUV can vary considerably and the time
lapse between FDG injection and acquisition is a major
contributor to this variation [27].
Follow-up is only worthwhile when patients comply to
a physician’s recommendations, and compliance with
medical advice has been a challenge since first described
by Hippocrates [28]. Numerous factors determine whether
a person’s behaviour coincides with medical advice, such
as the duration of therapy, the complexity of the regimen
and psychosocial factors [29]. Adherence to follow-up can
also be affected by a patients’ negative experience of
examinations such as discomfort and pain [30,31]. These
patient preferences may contribute to final decision mak-
ing on follow-up imaging, especially when modalities are
known to be equally effective. We formulated the hypoth-
esis that PET-MRI provides a less favourable experience
when compared to PET-CT, as the MRI examination may
elicit anxiety due to the need to remain immobile and
alone while enclosed in the MRI tunnel for a prolonged
period of time, in addition to the noise associated with
the examination [32].In this study, we solely focus on the ability of PET-MRI
to identify intrahepatic recurrences, since most recur-
rences after local treatment of the liver reoccur in the liver
[1,2]. However, a large group of patients will eventually
develop extrahepatic metastases or a local recurrence at
the site of the primary tumor. These are important predic-
tors of overall survival since they determine whether local
hepatic recurrences can still be treated [5]. PET-CT is
currently the modality of choice to rule out extra-hepatic
disease [33], but if PET-MRI proves to be effective in local
follow-up future studies should focus on extrahepatic
follow-up and the ability and feasibility of PET-MRI to
detect metastatic lesions throughout the body. In addition,
randomised controlled trials should be performed to
compare PET-CT and PET-MRI, or when one of the tech-
niques has proven to be significantly superior, an intense
versus a less intense follow-up protocol after thermal abla-
tion of CRLM and the effect on overall survival.
PET-MRI is currently only available in highly special-
ized hospitals. Before general implementation can be
pursued, the potential and limitations of this modality
need to be thoroughly investigated. In the current climate,
associated costs also play an important role in the imple-
mentation of diagnostic and treatment methods in daily
patient care. We are aware of only one study to date that
has addressed the cost-effectiveness of PET-CT after RFA
of hepatic malignancies [10]. These authors showed that
PET-CT is more cost-effective than independent use of
CT or MRI. However, as no study has yet addressed the
cost-effectiveness of using PET-MRI, long-term cost-
effectiveness, the results of future treatment and the
yield of different scan-moments all need to be assessed.
This study will contribute to the search for an optimal
follow-up protocol for patients treated with RFA or
MWA for CRLM. As minimally invasive procedures
become increasingly important in the treatment of the
oncologic patient, adequate staging of disease is essential
for optimal treatment results. This study may contribute
to improved staging and consequently to the effective
treatment of this ever-expanding patient group.
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